What will this cost us?

AND, who was begging who to do this deal?

https://www.globenewswire.com/news-release/2020/06/16/2048654/0/en/Zenith-Announces-Corporate-Update-Conference-Call-Webcast-on-June-18-2020-and-US-5-Million-Equity-Investment.html

conditional upon customary closing conditions and certain amendments to the previously announced license agreement between Zenith’s subsidiary, Zenith Epigenetics Ltd., and Newsoara Biopharma Co., Ltd., including the waiver of a potential future clinical development milestone payment and the assignment of patents in the territories to Newsoara Biopharma Co., Ltd. that are the subject of the license agreement, with Zenith retaining a right to re-acquire the patents for no additional consideration.

August 6, 2019

https://www.globenewswire.com/news-release/2019/08/06/1897559/0/en/Zenith-Epigenetics-and-China-Based-Newsoara-Biopharma-Announce-Licensing-Agreement-for-ZEN-3694.html

CALGARY, Alberta, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics” or the “Company”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma Co., Ltd. (“Newsoara”) for the Company’s lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau (the “Territories”). ZEN-3694 is currently in Phase 2 clinical development for the treatment of metastatic castration-resistant prostate cancer and triple negative breast cancer.

Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in the Territories. Newsoara will pay Zenith Epigenetics upfront and near-term development milestone payments totaling US$15 million.